The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): Results of a phase II study
Open accessAbstract
BACKGROUND: New systemic therapies are needed to improve the prognosis of patients with advanced‐stage hepatocellular carcinoma (HCC). In a Phase II trial involving previously untreated patients with advanced HCC, the more favorable schedule from a previous pilot study was evaluated. METHODS: Thirty‐four patients with previously untreated advanced‐stage HCC were prospectively enrolled. The GEMOX regimen consisted of gemcitabine 1000 mg/m 2 on Day 1 and oxaliplatin 100 mg/m 2 on Day 2. The treatment was repeated every 2 weeks until disease progression or limiting toxicity. RESULTS: Thirty‐two patients were assessable for efficacy and 33 for toxicity. In all, 323 treatment cycles were administered. No toxic deaths occurred. Hematological grade 3‐4 toxicity consisted of thrombocytopenia (27% of patients) and neutropenia (24%), including 2 febrile neutropenia and anemia (9%). Grade 3 oxaliplatin‐induced neurotoxicity was observed in 3 (9%) patients. The overall response rate was 18% (95% confidence interval [CI]: 8‐34) and disease stabilization was observed in 58% of patients (including 5 minor responses), giving a disease control rate of 76%. Median progression‐free and overall survival times were, respectively, 6.3 months (95% CI: 4.3‐10.1 months) and 11.5 months (95% CI: 8.5‐14.3 months). Treatment was significantly more effective in patients with nonalcoholic cirrhosis than in those with alcoholic cirrhosis. CONCLUSIONS: The GEMOX regimen seems to be well tolerated and active in advanced HCC, especially in patients with underlying nonalcoholic liver disease. A Phase II study of the GEMOX regimen plus cetuximab is ongoing. Cancer 2007. © 2007 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Cited by
Omata, M., Lesmana, L. A., Tateishi, R., Chen, P.-J., Lin, S.-M., Yoshida, H., Kudo, M., Lee, J. M., Choi, B. I., Poon, R. T. P., et al. (2010) · Hepatology International · doi:10.1007/s12072-010-9165-7 · Cited by 1,026
Qin, S., Bai, Y., Lim, H. Y., Thongprasert, S., Chao, Y., Fan, J., Yang, T.-S., Bhudhisawasdi, V., Kang, W. K., Zhou, Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.5643 · Cited by 500
Treatment of intermediate-stage hepatocellular carcinoma
Forner, A., Gilabert, M., Bruix, J., & Raoul, J.-L. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.122 · Cited by 466
Verslype, C., Rosmorduc, O., & Rougier, P. (2012) · Annals of Oncology · doi:10.1093/annonc/mds225 · Cited by 365
Hepatocellular carcinoma (HCC): beyond sorafenib—chemotherapy
Kim, D. W., Talati, C., & Kim, R. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.09.07 · Cited by 333
Metadata
- Authors
- Louafi, S., Boige, V., Ducreux, M., Bonyhay, L., Mansourbakht, T., de Baere, T., Asnacios, A., Hannoun, L., Poynard, T., & Taïeb, J.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2007-03
- Volume
- 109
- Issue
- 7
- Pages
- 1384-1390
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2087658241
- Cited by
- 195
- References
- 1
- FWCI
- 10.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.